Chemotherapy-induced peripheral neurotoxicity represents a debilitating complication that severely limits cancer treatment and diminishes survivor quality of life. Although alkylating regimens demonstrate lower clinical rates of neuropathy than platinum compounds, experimental models reveal substantial neuronal vulnerability. Recent laboratory investigations show that cyclophosphamide peripheral neurotoxicity arises from intense oxidative stress, mitochondrial injury, and sustained neuroinflammation in peripheral nerves. Fortunately, emerging research indicates that sodium-glucose cotransporter-2 (SGLT2) inhibitors offer profound cytoprotective properties beyond glycemic regulation. In a pioneering preclinical study, investigators evaluated whether the SGLT2 inhibitor remogliflozin could attenuate this debilitating neurotoxic injury in rodent models.

Mitigating Cyclophosphamide Peripheral Neurotoxicity Through SGLT2 Inhibition

The alkylating agent cyclophosphamide serves as a therapeutic cornerstone in diverse oncological and rheumatological protocols. However, hepatic bioactivation rapidly converts cyclophosphamide into toxic metabolites, notably acrolein and phosphoramide mustard. Consequently, these reactive byproducts trigger lipid peroxidation, deplete energy reserves, and compromise peripheral sensory and motor axons. In a controlled laboratory study, researchers evaluated twenty-four male Wistar rats allocated across four experimental groups over thirty days. One cohort received weekly intraperitoneal cyclophosphamide injections, while two therapeutic cohorts received concomitant oral remogliflozin at doses of 25 mg/kg/day or 50 mg/kg/day.

Significantly, animals receiving cyclophosphamide monotherapy developed marked deficits in sensorimotor performance, exhibiting impaired motor coordination and altered nociceptive sensitivity. Conversely, remogliflozin co-administration produced dose-dependent functional recoveries across standardized behavioral assessments. Rats treated with the higher 50 mg/kg/day dosage demonstrated substantial preservation of hindlimb coordination and normal tactile responses. Therefore, these functional behavioral outcomes confirmed that remogliflozin effectively countered the functional deficits characteristic of cyclophosphamide peripheral neurotoxicity.

Antioxidant Defense and Redox Homeostasis via Nrf2 Activation

Oxidative stress constitutes a primary pathophysiological driver of chemotherapy-induced nerve degeneration. Specifically, toxic alkylating intermediates exhaust endogenous free radical scavengers within vulnerable peripheral nerves. In this experimental model, cyclophosphamide monotherapy provoked pronounced biochemical derangements. The drug caused sharp declines in superoxide dismutase activity and substantially depleted endogenous glutathione reserves. Furthermore, toxic chemotherapy exposure elevated tissue concentrations of malondialdehyde, a classic hallmark of cellular lipid peroxidation.

However, remogliflozin therapy restored cellular redox equilibrium in a dose-dependent fashion. The drug markedly upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) expression across peripheral neural tissues. Because Nrf2 functions as the principal transcriptional driver of antioxidant defense, its activation promoted the synthesis of vital cytoprotective enzymes. Consequently, treated rats exhibited restored glutathione stores, normalized superoxide dismutase activity, and diminished malondialdehyde concentrations. Immunohistochemical evaluations confirmed pronounced Nrf2 immunoreactivity in peripheral nerve fibers. Thus, remogliflozin shields nervous tissue by directly enhancing endogenous enzymatic and non-enzymatic antioxidant defenses against reactive chemotherapeutic injury.

Suppression of Neuroinflammatory Cascades and Cytokine Release

Along with oxidative injury, neuroinflammation plays an indispensable role in accelerating axonal damage and neuropathic pain. Excessive reactive oxygen species stimulate nuclear factor kappa B (NF-κB), triggering persistent cytokine release. In the cyclophosphamide-treated group, researchers observed widespread neuroinflammatory signaling characterized by significant upregulation of NF-κB. Consequently, peripheral neural tissues accumulated excessive quantities of key proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). In addition, levels of monocyte chemoattractant protein-1 (MCP-1) rose sharply, facilitating the recruitment of activated macrophages into neural tissue.

Conversely, daily oral remogliflozin treatment blunted these destructive neuroinflammatory cascades. The compound substantially downregulated NF-κB concentrations, attenuating the transcription of inflammatory genes. Accordingly, treated rats exhibited notable reductions in TNF-α, IL-6, IL-1β, and MCP-1 within peripheral nerve specimens. By interrupting cytokine amplification loops, remogliflozin preserved the local microvascular architecture and prevented secondary neuroinflammatory destruction. Furthermore, these anti-inflammatory effects parallel observations from clinical cardiovascular trials, underscoring the systemic benefits of SGLT2 inhibition across diverse organ systems.

Upregulation of Neurotrophic Factors and Antiapoptotic Signaling

Beyond suppressing inflammation and oxidative stress, sustained axonal health demands the activation of intrinsic survival pathways. The experimental evaluation demonstrated that cyclophosphamide severely suppressed vital neurotrophic mediators. Specifically, untreated animals displayed significant reductions in brain-derived neurotrophic factor (BDNF) and cyclic AMP response element-binding protein (CREB). Furthermore, the cytotoxic regimen impaired prosurvival kinase cascades by depressing phosphoinositide 3-kinase (PI3K) and phosphorylated Akt (p-Akt) levels. Consequently, this molecular disruption activated mitochondrial apoptotic signaling, reflected by elevated proapoptotic BAX, depressed antiapoptotic BCL-2, and heightened caspase-3 cleavage.

Importantly, remogliflozin administration reversed this proapoptotic phenotype in a dose-dependent manner. Oral therapy augmented BDNF and CREB concentrations, establishing a microenvironment conducive to axonal repair. Moreover, remogliflozin restored PI3K levels and elevated the critical p-Akt to total Akt ratio. As a result, treated nerves exhibited increased BCL-2 expression alongside pronounced reductions in BAX and caspase-3 activity. Immunohistochemistry confirmed strong p-Akt immunoreactivity across nerve sheaths. Through synchronized PI3K/Akt activation and caspase suppression, remogliflozin prevented apoptotic cell death in vulnerable Schwann cells and peripheral axons.

Structural Preservation of Myelin and Translational Implications

Histological and ultrastructural examinations corroborated the functional and biochemical improvements observed in remogliflozin-treated animals. Sciatic nerve specimens from rats receiving cyclophosphamide alone exhibited severe pathology, characterized by disorganized nerve fibers, axonal vacuolation, and marked myelin degradation. In contrast, co-administration of remogliflozin maintained normal nerve architecture. Treated specimens displayed preserved axonal alignment, intact Schwann cell morphology, and significantly attenuated myelin sheath loss. These histopathological findings confirm that remogliflozin provides structural protection alongside biochemical modulation.

From a clinical perspective, these preclinical results carry notable implications for oncology practice. Although cyclophosphamide has a lower clinical incidence of neuropathy than taxanes, high-dose conditioning and prolonged therapy can cause debilitating nerve dysfunction. Currently, clinicians possess limited prophylactic agents to counter chemotherapy-induced peripheral neurotoxicity. Because SGLT2 inhibitors demonstrate established clinical safety and systemic cytoprotective benefits, repurposing them for neuroprotection represents an appealing strategy. However, oncology teams must await formal human clinical trials to verify efficacy and confirm that SGLT2 inhibition does not compromise antineoplastic therapeutic potency.

How does remogliflozin attenuate chemotherapy-induced peripheral nerve damage?

Remogliflozin mitigates nerve injury by modulating multiple cellular stress pathways simultaneously. Specifically, this SGLT2 inhibitor enhances endogenous antioxidant defenses via Nrf2 activation, effectively reducing toxic malondialdehyde accumulation. Furthermore, the molecule suppresses destructive proinflammatory cytokines, including TNF-alpha and interleukin-6, while activating neuroprotective PI3K/Akt signaling. Consequently, these synchronized biochemical actions prevent Schwann cell apoptosis, preserve structural myelin integrity, and restore functional motor coordination in experimental rodent models exposed to alkylating agents.

Why is cyclophosphamide neurotoxicity significant despite lower clinical incidence?

Although cyclophosphamide exhibits a lower clinical incidence of severe neuropathy compared to taxanes or platinum drugs, its reactive metabolites generate severe cellular damage. For example, acrolein and phosphoramide mustard induce intense mitochondrial oxidative stress and neuroinflammation. Consequently, patients receiving high cumulative doses or combination regimens often experience debilitating sensory disturbances and motor dysfunction. Therefore, developing targeted neuroprotective strategies remains essential to prevent long-term functional decline in affected oncology and rheumatology cohorts.

Can clinicians currently prescribe remogliflozin for peripheral neuropathy prevention?

Currently, remogliflozin is approved exclusively for managing type 2 diabetes mellitus, so clinicians cannot routinely prescribe it for neuroprotection. Although these preclinical findings provide compelling proof-of-concept data, researchers must complete rigorous human clinical trials first. Oncologists must confirm that remogliflozin does not compromise antineoplastic efficacy or alter chemotherapeutic pharmacokinetics before considering off-label administration. Therefore, healthcare providers should continue adhering to established evidence-based supportive care protocols until formal clinical trial outcomes emerge.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Almarghalani DA et al. Remogliflozin Attenuates Cyclophosphamide- Associated Peripheral Neurotoxicity in Rats: Concomitant Changes in Redox, Inflammatory, Neurotrophic, and Apoptosis-Related Markers. Toxicol Mech Methods. 2026 Sep 28. doi: 10.1080/15376516.2026.2740665. PMID: 42805919.
2. Salah H, et al. Emerging Therapeutic Strategies for Chemotherapy-Induced Peripheral Neuropathy: Current Evidence and Future Directions. Bahrain Med Bull. 2024;46(1):182-188.
3. Wiciński M, et al. Neuroprotective Effect of SGLT2 Inhibitors. Molecules. 2021;26(23):7270.